References:
  1. Orbach D, Sarnacki S, Brisse HJ, Gauthier-Villars M, Jarreau PH, Tsatsaris V, et al. Lancet Oncol. 2013 Dec;14(13)
  2. Sultan I, Casanova M, Al-Jumaily U, Meazza C, Rodriguez-Galindo C, Ferrari A. Soft tissue sarcomas in the first year of life.
  3. Eur J Cancer. 2010 Sep; 46(13): 2449-56.von Mehren M, Lor Randall R, DeLaney T, George S, Riedel R, Scheutze S, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Soft Tissue Sarcoma. (2014;2.2014:126)
  4. Tran QN, Kim AC, Gottschalk AR, Wara WM, Phillips TL, O’Donnell RJ, et al. Clinical outcomes of intraoperative radiation therapy for extremity sarcomas. Sarcoma. 2006;2006(1):91671. Pubmed Central PMCID: 1557794, Epub (2006/10/17)
  5. Fernandez-Pineda I, Neel MD, Rao BN. Current management of soft tissue sarcoma and Benign Tumors with Local Aggresiveness
  6. Laskar, S., Pilar, A., Khanna, N., Puri, A., Gulia, A., Qureshi, S., Ramadwar, M. Interstitial brachytherapy for pediatric soft tissue sarcoma: Evolving practice over three decades and long-term outcomes. Pediatric Blood & Cancer (2018)
  7. Orbach D, Rey A, Oberlin O, et al. Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2005;23:4363-71.
  8. Koscielniak E, Harms D, Schmidt D, et al. Soft tissue sarcomas in infants younger than 1 year of age: a report of the German Soft Tissue Sarcoma Study Group (CWS-81). Medical and pediatric oncology 1989;17:105-10.
  9. Spunt SL, Million L, Chi YY, et al. A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children’s Oncology Group prospective study. The Lancet Oncology 2020;21:145-61.